Can your race predict prostate cancer drug success?

NCT ID NCT03833921

Recruiting now Disease control Sponsor: Martha Mims Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 130 men with metastatic prostate cancer who are receiving standard treatment with abiraterone and prednisone. Researchers want to see if a person's race or ethnicity influences how well the drugs work, by measuring PSA levels and looking at genetic differences. Participants will be tracked for up to 10 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abiraterone acetate (Zytiga) and prednisone
What this could lead to: If successful, this could help doctors personalize prostate cancer treatment based on a patient's race or genetic background, improving outcomes.
What could go wrong: This is a Phase 2 observational study, not a large trial. It may not find clear links between race and treatment response, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATE CANCER METASTATIC

Contacts and locations

Locations

Ben Taub General Hospital
RECRUITING

Houston, Texas, 77030, United States
Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine
RECRUITING

Houston, Texas, 77030, United States
Michael E. DeBakey Veterans Affairs Medical Center
ACTIVE_NOT_RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.